Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Bioaffinity Technologies Inc (BIAF)

Bioaffinity Technologies Inc (BIAF)
0.6600 x 3 0.6834 x 1
Post-market by (Cboe BZX)
0.6834 -0.0177 (-2.52%) 04/04/25 [NASDAQ]
0.6600 x 3 0.6834 x 1
Post-market 0.6800 -0.0034 (-0.50%) 19:52 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6020
Day High
0.7793
Open 0.6900
Previous Close 0.7011 0.7011
Volume 2,612,700 2,612,700
Avg Vol 29,089,859 29,089,859
Stochastic %K 39.51% 39.51%
Weighted Alpha -82.05 -82.05
5-Day Change +0.4215 (+160.94%) +0.4215 (+160.94%)
52-Week Range 0.2404 - 3.1626 0.2404 - 3.1626
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,476
  • Shares Outstanding, K 18,256
  • Annual Sales, $ 2,530 K
  • Annual Income, $ -7,940 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 3.45
  • Price/Sales 1.37
  • Price/Cash Flow N/A
  • Price/Book 5.33
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings $-0.21 on 03/31/25
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2404 +184.28%
on 03/31/25
Period Open: 0.3300
1.5510 -55.94%
on 04/01/25
+0.3534 (+107.09%)
since 03/04/25
3-Month
0.2404 +184.28%
on 03/31/25
Period Open: 0.9400
1.5510 -55.94%
on 04/01/25
-0.2566 (-27.30%)
since 01/03/25
52-Week
0.2404 +184.28%
on 03/31/25
Period Open: 2.5800
3.1626 -78.39%
on 04/22/24
-1.8966 (-73.51%)
since 04/04/24

Most Recent Stories

More News
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

Despite weak economic data, the S&P 500 (SPX) closed higher to start the new quarter, as traders await President Donald Trump’s tariff policy rollout. In the face of financial turbulence, several promising...

BIAF : 0.6834 (-2.52%)
JYD : 0.3620 (-15.68%)
QSG : 4.17 (-19.96%)
CAR : 69.20 (-4.70%)
WOR : 46.46 (-3.35%)
ALMS : 10.05 (+17.68%)
SLNO : 67.48 (-6.49%)
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

The S&P 500 (SPX) closed higher to start the new quarter, despite some weak economic data, as traders await for President Donald Trump’s tariff policy rollout. However, several promising small-cap companies...

BIAF : 0.6834 (-2.52%)
JYD : 0.3620 (-15.68%)
QSG : 4.17 (-19.96%)
CAR : 69.20 (-4.70%)
WOR : 46.46 (-3.35%)
ALMS : 10.05 (+17.68%)
SLNO : 67.48 (-6.49%)
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip...

BIAF : 0.6834 (-2.52%)
CANF : 1.4700 (-2.65%)
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

Zacks Investment Research has recently initiated coverage of bioAffinity Technologies, Inc. BIAF, assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook...

BIAF : 0.6834 (-2.52%)
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

EQNX::TICKER_START (NASDAQ:INBS),(NASDAQ:CDIO),(NASDAQ:BIAF),(NASDAQ:TRIB),(NASDAQ:SOBR) EQNX::TICKER_END

TRIB : 0.5400 (-5.26%)
BIAF : 0.6834 (-2.52%)
INBS : 1.3500 (-5.59%)
CDIO : 0.3055 (-7.31%)
SOBR : 4.93 (+42.03%)
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks,...

ENLV : 0.8880 (-6.17%)
BIAF : 0.6834 (-2.52%)
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael...

BIAF : 0.6834 (-2.52%)
BIAFW : 0.2223 (-20.61%)
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will present at the Cleveland...

BIAF : 0.6834 (-2.52%)
BIAFW : 0.2223 (-20.61%)
bioAffinity Technologies to Ring Nasdaq Closing Bell Today

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will ring the Nasdaq Stock...

BIAF : 0.6834 (-2.52%)
NDAQ : 68.25 (-7.51%)
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported...

BIAF : 0.6834 (-2.52%)
BIAFW : 0.2223 (-20.61%)

Business Summary

bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO.

See More

Key Turning Points

3rd Resistance Point 0.9518
2nd Resistance Point 0.8655
1st Resistance Point 0.7745
Last Price 0.6834
1st Support Level 0.5972
2nd Support Level 0.5109
3rd Support Level 0.4199

See More

52-Week High 3.1626
Fibonacci 61.8% 2.0463
Fibonacci 50% 1.7015
Fibonacci 38.2% 1.3567
Last Price 0.6834
52-Week Low 0.2404

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades